1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Caliway Biopharmaceuticals Co Ltd

Caliway Biopharmaceuticals Co Ltd

TTWSE:6919
73.80
TWD
-2.20
(-2.89%)
-0.17EPS
155.33BMarket Cap
Nov 11Next Earn
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
(Taiwan Stock Exchange)

Recent

price

73.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
TWD
0.05
0.02
0.03
0.01
0.03
0.03
0.02
0.02
Revenue per Share
-0.35
-0.18
-0.49
-0.24
-0.39
-0.41
-0.23
-0.17
Basic EPS, GAAP
-0.34
-0.09
-0.27
-0.22
-0.35
-0.37
-0.29
-0.19
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.02
0.08
1.05
1.89
5.37
6.3
6.06
5.92
Book Value per Share
-0.02
0.08
1.05
1.89
5.37
6.3
6.06
5.92
Tangible Book Value per Share
350
534
461
1,171
1,239
1,430
1,543
1,561
Basic Weighted Avg Shares
19
10
12
13
39
44
38
29
Sales/Revenue/Turnover
-654.87
-1,020.3
-1,869.95
-2,493.17
-1,318.88
-1,613.95
-1,859.31
-2,827.47
Operating Margin (%)
22
18
23
25
28
30
31
31
Depreciation Expense
-122
-98
-224
-286
-488
-589
-352
-258
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-653.27
-951.56
-1,817.76
-2,232.1
-1,254.64
-1,325.18
-925.2
-877.11
Profit Margin (%)
-72
47
566
1,084
3,670
9,653
4,946
4,128
Working Capital
69
116
29
20
12
3
- -
98
LT Debt
-9
47
645
1,164
3,741
9,697
9,410
9,207
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-64.89
-31.64
-19.92
-8.76
-3.68
-2.77
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3
- -
10
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
98
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,553
1,556
1,556
Market Capitalization
240,711
134,314
155,328

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,991
5,029
4,198
Cash, Cash Equivalents & STI
4,860
4,889
4,047
Accounts Receivable, Net
6
- -
- -
Inventories
3
3
5
Total Current Liabilities
45
111
70
Payables & Accruals
- -
- -
- -
ST Debt
3
- -
10
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
348.34%
-2.95%
Free Cash Flow
- -
66.58%
-16.94%
Net Income, GAAP
- -
41.27%
-40.23%
Sales/Revenue/Turnover
- -
45.31%
-14.4%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4
8
23
9
44
2025
- -
12
13
12
38
2026
- -
4
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.16
-0.13
-0.1
-0.04
-0.41
2025
-0.11
-0.16
- -
0.05
-0.23
2026
-0.07
-0.14
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Caliway Biopharmaceuticals Co., Ltd. (TWSE:6919) develops small-molecule therapeutics for medical aesthetics and inflammatory diseases. The company, founded in 2012 and headquartered in New Taipei City, Taiwan, focuses on unmet needs in areas such as non-surgical fat reduction, cellulite, hyperpigmentation, skin aging, Dercum's disease, osteoarthritis, and central obesity; its lead product, CBL-514, is a first-in-class injectable that induces targeted adipocyte apoptosis for subcutaneous fat reduction, cellulite treatment, and Dercum's disease, currently advancing through global Phase 3 trials including SUPREME-01; CBL-539 comprises a long-acting injectable for refractory melasma via melanin inhibition and skin elasticity improvement through collagen production; CBF-520 targets central obesity in preclinical development; the company also pursues combination therapies with GLP-1 receptor agonists for weight rebound management and offers dietary supplements. Caliway operates primarily in the biotechnology sector, targeting global markets with high-potential indications exceeding $10 billion in value, and plans regional authorizations in Taiwan, China, Korea, and Southeast Asia alongside global licensing partnerships. Recent developments include FDA clearance and IND approval for the SUPREME-01 Phase 3 study of CBL-514 in July 2025, Health Canada approval for the same trial in August 2025 with U.S.-Canada recruitment underway, inclusion in the MSCI Global Standard Index effective August 2025, successful End-of-Phase 2 meeting with FDA in May 2025 confirming pivotal design for abdominal fat reduction NDA, positive Phase 2 cellulite results in 2024 with over 95% improvement rates, and preclinical data presentations on CBL-514-GLP-1 combinations at EASD 2025 and BIO 2025.